Jefferies Upgrades Corbus Pharmaceuticals to Buy, Raises Price Target to $46
Jefferies Upgrades Corbus Pharmaceuticals to Buy, Raises Price Target to $46
傑富瑞將Corbus Pharmicals上調爲收購,將目標股價上調至46美元
Jefferies analyst Maury Raycroft upgrades Corbus Pharmaceuticals (NASDAQ:CRBP) from Hold to Buy and raises the price target from $4 to $46.
傑富瑞分析師莫里·雷克羅夫特將Corbus Pharmicals(納斯達克股票代碼:CRBP)從 “持有” 上調至 “買入”,並將目標股價從4美元上調至46美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。